An observational study in Pterygium, sponsored by Balikesir University. Not yet recruiting at 1 site in Turkey. Per ClinicalTrials.gov, last updated 2023-09-18.
Sponsored by Balikesir University · Observational
Purpose: Pterygium is a common ocular surface disease defined by fibrovascular conjunctival growth extending onto the cornea. Its pathogenesis remains unclear. In severe cases, it may extend into the central cornea, inducing irregular corneal astigmatism and causing loss of vision. CD44( phagocytic glycoprotein-1 ) is involved in the organization of certain cellular processes, for instance, cell adhesion, division, and migration, by binding with its main ligand, hyaluronic acid. Proliferating cell nuclear antigen (PCNA) is a proliferation marker in the nucleus. E-cadherin is a calcium-dependent transmembrane glycoprotein that plays a significant role in the protection of tissue integrity and cell-to-cell adhesion. This study aimed to determine the role of CD44, proliferating cell nuclear antigen (PCNA), and E-cadherin in pterygium formation and recurrence.
Methods:60 patients with pterygium will be enrolled in the study and conjunctival samples will be collected from 30 patients to form the control group. CD44, PCNA and E-cadherin expressions in surgically removed pterygium will be compared with tissue samples from normal control group.
IBM SPSS (statistical software) version 26.0 will be used for statistical analyses.
109 studies on the registry are indexed under Pterygium; 9 are open to participants now.
This study's planned enrollment of 60 is close to the median of 58 across 14 observational studies indexed under Pterygium.
Browse Pterygium studies →Balikesir University is the lead sponsor of 62 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
60 patient with primary and recurrent pterygium
Inclusion Criteria: patient with pterygium -
Exclusion Criteria: patient with pseudopterygium
-
group 1 -control group normal conjunctiva from 30 patients
Other: Expression of CD44, E-cadherin and PCNA
primary pterygia samples from 30 patients
Other: Expression of CD44, E-cadherin and PCNA
recurrent pterygia samples from 30 patients
Other: Expression of CD44, E-cadherin and PCNA
The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)
Immunohistochemistry
Thin sections will be taken from paraffin embedded tissue samples and placed on barcode glass slides After deparaffinization and rehydration, the sections will be subjected to histopathological evaluation using hematoxylin and eosin staining.We use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval
Time frame: up to three weeks after pterygium surgery
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Balikesir University